Merck And Moderna Initiate INTerpath-009 Phase 3 Trial Of V940 (mRNA-4157), An Investigational Individualized Neoantigen Therapy In Combination With Keytruda (Pembrolizumab) As Adjuvant Treatment After Neoadjuvant Keytruda And Chemotherapy In Patients With Certain Types Of Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck and Moderna have started a Phase 3 trial for V940 (mRNA-4157), an investigational therapy, in combination with Keytruda for certain non-small cell lung cancer patients.
October 28, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck has initiated a Phase 3 trial for V940 in combination with Keytruda, potentially enhancing its oncology portfolio.
The initiation of a Phase 3 trial for a new cancer treatment indicates potential future revenue streams and strengthens Merck's position in oncology.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Moderna is collaborating with Merck on a Phase 3 trial for V940, showcasing its mRNA technology in cancer treatment.
Moderna's involvement in a Phase 3 trial highlights the application of its mRNA technology beyond vaccines, potentially opening new markets.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80